



NEW THERAPEUTICS FOR AGING DISEASES

[Press release](#)

Biophytis Appoints Ivana Kim, M.D., as a Scientific Advisor to Support Design of Company's Planned Phase IIb Study of MACULIA in Dry AMD

Paris (France) & Cambridge (Mass), 2 February 2016 – Biophytis (Alternext Paris: ALBPS), a geriatric medicine company advancing clinical stage drug-candidates to treat sarcopenic obesity and age related macular degeneration (AMD), announced today the appointment of Ivana K. Kim, M.D., as a scientific advisor to support the Company's MACULIA clinical development program. Dr. Kim will contribute to Biophytis' clinical development and regulatory strategies by guiding clinical development plans and protocols for the Company's product candidates and clinical trials, as well as reviewing regulatory materials. She will also serve as a scientific advisor to Biophytis for meetings with national and international medical and pharmaceutical regulators, agencies and authorities.

"We are pleased to have Dr. Kim join our team as we continue to advance our MACULIA development program," said Stanislas Veillet, Ph.D., CEO of Biophytis. "Her vast knowledge of and substantial experience in ophthalmology, ophthalmic oncology and macular degeneration will be critical to us as we prepare to conduct our Phase IIb clinical trial in dry AMD in the third quarter of 2016. Dr. Kim will play a key role in Biophytis' clinical and regulatory plans, going forward."

As a member of the Retina Service and Director of the Macular Degeneration Unit at Massachusetts Eye and Ear, Dr. Kim specializes in the medical and surgical treatment of patients with vitreoretinal diseases, including age-related macular degeneration, retinal detachment, and uveal melanoma. In addition to her clinical responsibilities, Dr. Kim is Co-Director of the Harvard Medical School Department of Ophthalmology Age-Related Macular Degeneration (AMD) Center of Excellence - a multidisciplinary collaboration among clinicians and scientists who are pooling their knowledge and resources with the goal of advancing breakthroughs in treatment for patients with AMD. Dr. Kim received her medical training at Harvard Medical School (HMS.) She deepened her knowledge of the eye as a resident in the HMS Department of Ophthalmology Residency Training Program, and subsequently, as a retina fellow at Mass. Eye and Ear.

About 90 percent of all people with age-related macular degeneration have "dry" AMD, a condition which layers of the macula (including the photoreceptors and the retinal pigment epithelium) get progressively thinner, functioning less and less as they do.

Maculia are orally available subtype selective PPAR alpha agonists, which have demonstrated preclinical proof concept for age related macular degeneration and satisfactory safety and tolerability in Phase I testing. The lead drug-candidate in the Maculia program, BIO 201, is expected to enter Phase IIb clinical trials in 2016. To learn more, please visit: <http://www.biophytis.com/en/pipeline/plateforme-maculia/>

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarcob (BIO101) to treat sarcopenic obesity and Maculia (BIO201) to treat dry age-related macular degeneration (AMD).

The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also

collaborates with scientists at the Institute of Myology, and the Vision Institute.
BIOPHYTIS is eligible for the French PEA-PME regime.

Biophytis

Stanislas Veillet

CEO

contact@biophytis.com

Tel : +33 1 41 83 66 00

Milestones

Bruno Arabian

barabian@milestones.fr

Tel : +33 1 83 62 34 84

Mob : +33 6 87 88 47 26

LifeSci Advisors

Chris Maggos

Managing Director, Europe

chris@lifesciadvisors.com

Mob : +41 79 367 6254